A61P 15 - Drugs for genital or sexual disorders; Contraceptives

Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635)
11/2002
11/14/2002	WO2002090349A1 N-oxide anthranylamide derivatives and their use as medicaments
11/14/2002	WO2002090348A1 Sulfonamides
11/14/2002	WO2002090337A1 Sulfonamides
11/14/2002	WO2002090330A1 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives
11/14/2002	WO2002090317A1 Substituted cyclohexane-1,4-diamine derivatives
11/14/2002	WO2002090025A1 Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application
11/14/2002	WO2002089858A1 Azo compounds for type i phototherapy
11/14/2002	WO2002089818A1 Use of sucralfate for the treatment of cervical erosion
11/14/2002	WO2002089802A2 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
11/14/2002	WO2002089800A2 N-aroyl cyclic amine derivatives as orexin receptor antagonists
11/14/2002	WO2002089793A1 Sulfonamides
11/14/2002	WO2002089792A1 Sulfonamides
11/14/2002	WO2002089787A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	WO2002089785A1 Sulfonamides
11/14/2002	WO2002089783A1 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties
11/14/2002	WO2002089740A2 Sulfonamides
11/14/2002	WO2002076476A3 Prodrugs of anticancer agents employing substituted aromatic acids
11/14/2002	WO2002066028A3 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids
11/14/2002	WO2002055013A3 Therapeutic chromone compounds
11/14/2002	WO2002055012A3 Therapeutic heterocyclic compounds
11/14/2002	WO2002018623A3 Methods and reagents for protease inhibition
11/14/2002	WO2002007718A8 Method for the treatment of climacteric disorders in women during or after the menopause
11/14/2002	US20020169317 Oxazinocarbazoles for the treatment of CNS diseases
11/14/2002	US20020169209 Potentiation of therapeutic effects of fatty acids
11/14/2002	US20020169203 Modulators of all three classes of calcium channel blocker subtypes (Small, Intermediate and Big conductance K channel (SK, IK and BK)) comprising malonate esters and nitriles; respiratory, brain, cardiovascular, urogenital disorders
11/14/2002	US20020169202 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
11/14/2002	US20020169198 Agonists of the progesterone receptor; contraceptives, hormone replacement therapy and treating menopause symptoms
11/14/2002	US20020169174 Xanthine phosphodiesterase V inhibitors
11/14/2002	US20020169170 Arylpiperazines having activity at the serotonin 1A receptor
11/14/2002	US20020169166 Benzimidazoles that are useful in treating sexual dysfunction
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020169144 Angiogenesis inhibition
11/14/2002	US20020168754 Nucleotide sequences coding polypeptides for use in the treatment of gastric, testicular, retinal, nervous system and immunological disorders
11/14/2002	US20020168716 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of tumors, immunological, autoimmune, skin, viral, bone, nervous system and inflammatory disorders
11/14/2002	US20020168433 Plant extracts; mixture of isoflavones, lignan, saponin, catechin and benzoic acid
11/14/2002	US20020168382 Inducing immunology response
11/14/2002	US20020168344 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
11/14/2002	DE10122894A1 New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
11/14/2002	CA2453223A1 Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors
11/14/2002	CA2446857A1 Reproductive cancer diagnosis and therapy
11/14/2002	CA2446735A1 Substituted cyclohexane-1,4-diamine derivatives with an anti-diarrhoea and peripheral analgesic action
11/14/2002	CA2446396A1 N-aroyl cyclic amines
11/14/2002	CA2446365A1 Sulfonamides
11/14/2002	CA2446363A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	CA2445982A1 Sperm-specific cation channel, and uses therefor
11/14/2002	CA2435142A1 Kinases and phosphatases
11/14/2002	CA2385809A1 Alkylamide compounds
11/13/2002	EP1256583A1 Pyrimidine-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
11/13/2002	EP1256578A1 Thiazole derivatives and their use as cdk inhibitors
11/13/2002	EP1255835A2 Polypeptides and nucleic acids encoding same
11/13/2002	EP1255831A2 Sperm specific proteins
11/13/2002	EP1255764A1 Purine derivatives
11/13/2002	EP1255751A2 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors
11/13/2002	EP1255740A2 Substituted arylpyrazines
11/13/2002	EP1255738A2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
11/13/2002	EP1255552A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction
11/13/2002	EP1255536A2 Indolinone derivatives for modulation of c-kit tyrosine protein kinase
11/13/2002	EP1107968B1 Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one
11/13/2002	CN1379776A Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation
11/13/2002	CN1379767A Isoxazolecarboxamide derivatives
11/13/2002	CN1379669A Valdecoxib compositions
11/13/2002	CN1379666A Non-peptide GnRH agents, methods and intermediates for their preparation
11/13/2002	CN1378856A Chinese medicine for treating gynopathy
11/13/2002	CN1378840A Slow-releasing composition of estrogen medicine and its preparing process
11/12/2002	US6479545 Formulation for menopausal women
11/12/2002	US6479544 Therapeutic combinations of fatty acids
11/12/2002	US6479517 Treatment of post-menopausal syndrome: osteoporosis, cardiovascular effects such as hyperlipidemia, and estrogen-dependent cancer, particularly breast and uterine cancer
11/12/2002	US6479497 Compounds having a selective effect at a subgroup of 5-hydroxytryptamine receptors, designated the h5-ht1b receptor
11/12/2002	US6479490 Treatment of diseases characterized by excess th2 cytokines and/ or an excess ige production.
11/12/2002	US6479475 Oral contraceptive
11/12/2002	US6479051 Oral administration of lactobacillus for the treatment and prevention of urogenital infection
11/12/2002	CA2055948C Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria
11/11/2002	CA2385692A1 Thiazole derivatives
11/07/2002	WO2002088664A2 Control of compactability through crystallization
11/07/2002	WO2002088316A2 G-protein coupled receptors
11/07/2002	WO2002088314A2 Ovary-specific genes and proteins
11/07/2002	WO2002088146A2 ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H-[1,4]DIOXINO[2,3-e]INDOLE
11/07/2002	WO2002088144A2 ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-f]QUINOXALINE
11/07/2002	WO2002088143A2 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
11/07/2002	WO2002088140A1 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene
11/07/2002	WO2002088139A1 6h-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
11/07/2002	WO2002088135A1 Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans
11/07/2002	WO2002088131A1 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta[a]naphthalene
11/07/2002	WO2002088123A1 Chemical compounds
11/07/2002	WO2002088121A1 Pyrazolo[1,5-a]pyridines and medicines containing the same
11/07/2002	WO2002088095A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	WO2002088093A1 Benzimidazoles that are useful in treating sexual dysfunction
11/07/2002	WO2002087626A1 Pharmaceutical compositions comprising dendritic cells for immunotherapy of autoimmune disease and treatment methods using the same
11/07/2002	WO2002087593A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
11/07/2002	WO2002087570A1 Composition comprising antifungal agents for treating vulvovaginitis and vaginosis
11/07/2002	WO2002087562A1 Use of protein and essential amino acids to treat amenorrhea and related disorders
11/07/2002	WO2002087548A1 A pharmaceutical tablet having a high api content
11/07/2002	WO2002087465A2 Compositions and methods of double-targeting virus infections and cancer cells
11/07/2002	WO2002064546A3 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
11/07/2002	WO2002051421A3 Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism
11/07/2002	WO2002028897A3 Human g-protein coupled receptor and uses thereof
11/07/2002	WO2001027079A9 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
11/07/2002	US20020165399 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
11/07/2002	US20020165380 A nucleic acid probe consisting a nucleic acid molecule of at least 15 nucleotides which is complementary to the antisense sequence of a unique fragment of the sequence of a nucleic acid molecule encoding a mammalian fb41 receptor
11/07/2002	US20020165374 Secreted protein HFEAF41

1 ... 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 ... 557